Try our Advanced Search for more refined results
August 02, 2017
AbbVie Inc. et al v. Boehringer Ingelheim International GMBH et al
Case Number:
1:17-cv-01065
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
May 14, 2019
Boehringer Waves White Flag In Humira Patent Battle
Boehringer Ingelheim on Tuesday abandoned its long-shot assault on the patent fortress surrounding AbbVie Inc.'s immunosuppressant Humira, saying it would reluctantly join a long list of biosimilar makers that have agreed to delay competition until 2023.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login